In response to EGFR-TKI therapy of non-small-cell lung carcinoma (NSCLC), Notch3 physically binds to β-catenin in the cytoplasm of tumor cells to activate β-catenin signaling (Arasada et al., 2018). This evidence concerns the gene EGFR and neoplasm.